COMPREHENSIVE CIRCRNA ANALYSIS REVEALS MOLECULAR INTERACTIONS RELATED TO POOR OVERALL SURVIVAL IN MULTIPLE MYELOMA

COMPREHENSIVE CIRCRNA ANALYSIS REVEALS MOLECULAR INTERACTIONS RELATED TO POOR OVERALL SURVIVAL IN MULTIPLE MYELOMA

Multiple myeloma (MM) is one of the most common hematologic malignancies, characterized by uncontrolled proliferation of plasma cells in the bone marrow. Investigating MM epigenetics at the non-coding RNAs (ncRNAs) level and their interactions can be a key factor in understanding this disease. Circu...

Full description

Bibliographic Details
Main Authors:	LRD Merces, L Magalhães, GBS Souza, AVVD Berg, AKCRD Santos
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137923009756

Similar Items

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
by: Bei Wang, et al.
Published: (2022-10-01)

THE EFFECT OF BISPHOSPHONATE USE ON TREATMENT RESPONSE AND OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS
by: Ayşe Uysal, et al.
Published: (2021-11-01)

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
by: Rebmann, V, et al.
Published: (2007)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
by: Rasmus Sørrig, et al.
Published: (2017-01-01)

PB2119: REDUCED OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS DURING THE COVID-19 PANDEMIC
by: Alexander Luchinin, et al.
Published: (2023-08-01)

The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
by: Yildiz Ipek, et al.
Published: (2023-06-01)

Predictive Value of the Hematopoietic Stem Cell Transplantation - Comorbidity Index for Overall Survival in Patients with Multiple Myeloma
by: Tayfun Elibol, et al.
Published: (2022-11-01)

A Precisely Calculated Neutrophil to Lymphocyte Ratio could Predict Overall Survival in Multiple Myeloma Patients
by: Hasan Jalaeikhoo, et al.
Published: (2018-07-01)

NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma
by: Xingxing Jian, et al.
Published: (2022-09-01)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
by: Ga-Young Song, et al.
Published: (2020-08-01)

Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification
by: Jiaxuan Xu, et al.
Published: (2022-10-01)

774 Antibiotic administration prior to immunotherapy leads to poor overall survival across multiple malignancies
by: Trisha Wise-Draper, et al.
Published: (2020-11-01)

Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients
by: Tingting Qi, et al.
Published: (2020-12-01)

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
by: Xinhe Shan, et al.
Published: (2023-05-01)

Comprehensive Analysis of CircRNA Expression Profiles in Multiple Tissues of Pigs
by: Qingpeng Shen, et al.
Published: (2023-11-01)

Machine Learning–Based Overall Survival Prediction of Elderly Patients With Multiple Myeloma From Multicentre Real-Life Data
by: Li Bao, et al.
Published: (2022-06-01)

SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE
by: Stergios Intzes, et al.
Published: (2021-01-01)

CircRNAs in diagnosis, prognosis, and clinicopathological features of multiple myeloma; a systematic review and meta-analysis
by: Yasin Mirazimi, et al.
Published: (2023-08-01)

Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related myocardial damage
by: Runjie Sun, et al.
Published: (2021-06-01)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
by: Fatih M. Uckun, et al.
Published: (2023-06-01)

Macroglossia reveals multiple myeloma
by: Maria Bonvicini, et al.
Published: (2021-11-01)

Comprehensive CircRNA Profiling and Selection of Key CircRNAs Reveal the Potential Regulatory Roles of CircRNAs throughout Ovarian Development and Maturation in <i>Cynoglossus semilaevis</i>
by: Jing Li, et al.
Published: (2021-08-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS
by: Ecenur Guder Arslan, et al.
Published: (2023-10-01)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
by: Shuangshuang Jia, et al.
Published: (2022-03-01)

Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.
by: Zarko Manojlovic, et al.
Published: (2017-11-01)

The molecular pathogenesis of multiple myeloma
by: Niccolò Bolli, et al.
Published: (2020-12-01)

Molecular characterization of multiple myeloma
by: Buse Zeren Kiremitci, et al.
Published: (2022-07-01)

Low expression of IGFBP4 and TAGLN accelerate the poor overall survival of osteosarcoma
by: Yue Xi, et al.
Published: (2022-06-01)

Low TYROBP expression predicts poor prognosis in multiple myeloma
by: Hong Luo, et al.
Published: (2024-03-01)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
by: Benjamin G. Barwick, et al.
Published: (2019-04-01)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
by: Damian Mikulski, et al.
Published: (2021-12-01)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-02-01)

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
by: Katarina Uttervall, et al.
Published: (2014-01-01)

Comprehensive elaboration of circular RNA in multiple myeloma
by: Chunsheng Zhu, et al.
Published: (2022-08-01)

3 years survival of patients with multiple myeloma.
by: Julio Dámaso Fernández Águila, et al.
Published: (2006-12-01)

Socioeconomic Factors and Survival of Multiple Myeloma Patients
by: Kamal Chamoun, et al.
Published: (2021-02-01)

3 years survival of patients with multiple myeloma.
by: Julio Dámaso Fernández Águila, et al.
Published: (2006-12-01)

Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma
by: Fan Zhou, et al.
Published: (2020-01-01)

P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: C. Nozzoli, et al.
Published: (2023-05-01)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Evangelos Terpos, et al.
Published: (2022-04-01)